Literature DB >> 19349029

Pulmonary atresia, VSD and Mapcas: repair without unifocalization.

Christian P Brizard1, Matthew Liava'a, Yves d'Udekem.   

Abstract

The last three decades have seen considerable development in the management of infants with pulmonary atresia, ventricular septal defect, and major aorto-pulmonary collaterals. The technical difficulty of surgical treatment lies in the fashioning of a pulmonary vascular bed capable of providing suitably low right ventricular pressure for repair of the intracardiac defect. With the current trend toward early and complete unifocalization of major aortopulmonary collateral arteries (mapcas), we describe an alternative approach - "repair without unifocalization" - and explain our reasoning for pursuing this technique.

Entities:  

Mesh:

Year:  2009        PMID: 19349029     DOI: 10.1053/j.pcsu.2009.01.016

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu        ISSN: 1092-9126


  4 in total

Review 1.  Surgical strategies for pulmonary atresia with ventricular septal defect associated with major aortopulmonary collateral arteries.

Authors:  Akio Ikai
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-05-25

2.  Outcomes of Patients with Pulmonary Atresia and Major Aortopulmonary Collaterals Without Intervention in Infancy.

Authors:  Michael L O'Byrne; Joshua P Kanter; John T Berger; Richard A Jonas
Journal:  Pediatr Cardiol       Date:  2016-07-05       Impact factor: 1.655

3.  Homograft durability after correction of pulmonary atresia and ventricular septal defect with or without systemic pulmonary collateral arteries.

Authors:  Pieter C van de Woestijne; Jamie L R Romeo; Ingrid van Beynum; Maarten Witsenburg; M Mostafa Mokhles; Ad J J C Bogers
Journal:  JTCVS Open       Date:  2021-09-24

4.  Staged correction of pulmonary atresia, ventricular septal defect, and collateral arteries.

Authors:  Pieter van de Woestijne; Mostafa Mokhles; Ingrid van Beynum; Peter de Jong; Jeroen Wilschut; Ad Bogers
Journal:  J Card Surg       Date:  2022-02-09       Impact factor: 1.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.